Search Results - "van der Weide, M C Jansen"

The patient's view on rare disease trial design - a qualitative study by Gaasterland, C M W, van der Weide, M C Jansen, du Prie-Olthof, M J, Donk, M, Kaatee, M M, Kaczmarek, R, Lavery, C, Leeson-Beevers, K, O'Neill, N, Timmis, O, van Nederveen, V, Vroom, E, van der Lee, J H

“…Clinical trials in rare diseases are more challenging than trials in frequent diseases. Small numbers of eligible trial participants, often complicated by…”
Get full text

Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation by Gaasterland, C M W, van der Weide, M C Jansen, Roes, K C B, van der Lee, J H

“…Goal Attainment Scaling (GAS) is an instrument that is intended to evaluate the effect of an intervention by assessing change in daily life activities on an…”
Get full text

The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging by Dorrius, M. D., Pijnappel, R. M., van der Weide Jansen, M. C., Jansen, L., Kappert, P., Oudkerk, M., Sijens, P. E.

“…Objective To determine whether quantitative multivoxel MRS improves the accuracy of MRI in the assessment of breast lesions. Methods Twenty-five consecutive…”
Get full text

The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design by Gaasterland, C.M.W., Jansen-van der Weide, M.C., Vroom, E., Leeson-Beevers, K., Kaatee, M., Kaczmarek, R., Bartels, B., van der Pol, W.L., Roes, K.C.B., van der Lee, J.H.

“…•With the POWER-tool, patients can be involved in research design.•The model provides a method to choose outcome measures with patients.•The model is developed…”
Get full text

Semi-automatic measurement of left ventricular function on dual source computed tomography using five different software tools in comparison with magnetic resonance imaging by de Jonge, G.J, van der Vleuten, P.A, Overbosch, J, Lubbers, D.D, Jansen-van der Weide, M.C, Zijlstra, F, van Ooijen, P.M.A, Oudkerk, M

“…Abstract Purpose To compare left ventricular (LV) function assessment using five different software tools on the same dual source computed tomography (DSCT)…”
Get full text

The negative predictive value of breast Magnetic Resonance Imaging in noncalcified BIRADS 3 lesions by Dorrius, M.D, Pijnappel, R.M, Sijens, P.E, van der Weide, M.C. Jansen, Oudkerk, M

“…Abstract Purpose The purpose of this study is to determine whether breast MRI can provide a sufficient NPV to safely rule out malignancy in mammographic BIRADS…”
Get full text

Breast magnetic resonance imaging as a problem-solving modality in mammographic BI-RADS 3 lesions by Dorrius, M D, Pijnappel, R M, Jansen-van der Weide, M C, Oudkerk, M

“…The probability of a mammographic Breast Imaging Reporting and Data System (BI-RADS) 3 lesion being cancer is considered to be less than 2%. Therefore, the…”
Get full text

Granted, undecided, withdrawn and refused requests for euthanasia and physician-assisted suicide in the Netherlands; 2000-2002 by Onwuteaka-Philipsen, B D, Jansen-Van der Weide, M C, Van der Wal, G

“…To determine the characteristics of patients who request euthanasia or physician-assisted suicide and whether these characteristics differ among those whose…”
Get more information

When being ‘tired of living’ plays an important role in a request for euthanasia or physician-assisted suicide: patient characteristics and the physician's decision by Rurup, Mette L., Onwuteaka-Philipsen, Bregje D., Jansen-van der Weide, Marijke C., van der Wal, Gerrit

“…In the Netherlands physicians are allowed to grant requests for euthanasia or physician-assisted suicide (EAS) if they meet several requirements of due care…”
Get full text

Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden by Feller, Nicole, Jansen-van der Weide, Martine C., van der Pol, Marjolein A., Westra, Guus A.H., Ossenkoppele, Gert J., Schuurhuis, Gerrit Jan

“…Minimal residual disease (MRD) present in peripheral blood stem cell (PBSC) products of AML patients may contribute to relapse. Our goal was to 1) predict…”
Get full text